A Fourteen-day Experience with Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS): An Iranian Treatment Protocol
(ندگان)پدیدآور
Jamaati, HamidrezaDastan, FarzanehTabarsi, PayamMarjani, MajidSaffaei, AliHashemian, Seyed MohammadRezaنوع مدرک
TextResearch article
زبان مدرک
Englishچکیده
COVID-19 is currently causing concern in the medical community as the virus is spreadingaround the world. It has a heavy global burden, particularly in low-income countries. The clinicalspectrum of COVID-19 pneumonia ranges from mild to critically ill cases and Acute RespiratoryDistress Syndrome. An expert panel was held and an internal protocol was developed to managethe COVID-19 induced ARDS according to WHO recommendations and NIH guidelines.Different therapeutic regimens were employed on this protocol based on the ARDS severity andthe patients' special characteristics. The mortality rate, the rate of survivors, and non-survivorswere reported. Of the 231 suspected cases of COVID-19 admitted to the hospital during twoweeks, 72 patients were admitted to ICU with diagnosis confirmed by RT-PCR. In total, mortalityin the ICU was 25% (n = 18) among ARDS patients over two weeks. COVID-19 induced ARDSis a major concern. The rapid progression of ARDS needs specific protocol based on patients'characteristics and rapid action.
کلید واژگان
COVID-19Coronavirus
Acute respiratory distress syndrome
Treatment
Pharmacotherapy (Clinical Pharmacy)
شماره نشریه
1تاریخ نشر
2020-02-011398-11-12
ناشر
School of Pharmacy, Shahid Beheshti University of Medical Sciencesسازمان پدید آورنده
Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. | Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Student Research Committee, Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
شاپا
1735-03281726-6890




